Management for asthma and COPD during COVID-19

Guidance suggests: 

  • Patients presenting with an asthma or COPD exacerbation should be managed according to current guidance. The shortest duration of increased ICS or oral corticosteroids to gain control should be used
  • There is no evidence that ICS increase the risks associated with COVID-19 infection
  • For COPD exacerbation consider carefully whether the benefits of oral steroids will outweigh the risks of worsening any viral illness. Ensure you are advising that the control of symptoms with increased bronchodilation, breathing exercises and pacing, for example and where appropriate, can be highly effective. The absence of high blood eosinophil counts in past FBCs suggests a COPD phenotype with less steroid responsiveness and here, avoidance of steroids is justifiable.